Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06384053
Other study ID # SAHARA Trial
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2024
Est. completion date July 1, 2028

Study information

Verified date April 2024
Source Kantonsspital Winterthur KSW
Contact Nidar Batifi, MSc
Phone 0522665361
Email study-coordination-radiotherapy@ksw.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC).


Description:

The SAHARA Trial is investigating if adding hyperthermia to radiotherapy (RT) can enhance treatment outcomes by making cancer cells more sensitive to radiation, thus requiring lower doses and potentially reducing side effects. The trial compares high-dose RT alone with de-escalated RT plus hyperthermia. The aim is to demonstrate that the combination is non-inferior to standard RT in treating non-melanoma skin cancer (NMSC). The trial is designed for elderly people of 65 years or older.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date July 1, 2028
Est. primary completion date July 1, 2026
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Personally signed and dated written informed consent - Histologically confirmed invasive non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of any differentiation - = T2 (TNM Classification 8th Edition) - Tumor thickness up to 2cm (Maximum Depth invasion and/or exophytic growth, measured on pathology report or imaging) - Local recurrence allowed, if primary treatment longer ago than 6 months (after primary treatment other than radiotherapy (RT)) - Age = 65 years - Eastern Cooperative Oncology Group (ECOG) performance status 0-2, with a life expectancy of more than 6 months - Presentation at the Swiss Hyperthermia Network (SHN) tumor conference mandatory Exclusion Criteria: - Other histology than BCC or SCC - T1 tumor and/or N+ (according to TNM classification 8th edition) - Tumors after resection (R1 or R2 as well as adjuvant indication) - Tumor invasion into critical areas - Several lesions exceeding the capacity of one treatment/radiation field (multiple lesions within one treatment field are acceptable) - Previous (one month) or concurrent Chemo- or Immunotherapy - Patients with connective tissue disorders (e.g. Sclerodermia, Lupus erythematodes) - Lesions inside or in proximity (within 3cm) previously irradiated area - Medical immunosuppression - wIRA-specific exclusion criteria - Tattoos in irradiated area - Increased photosensitivity (either due to simultaneous treatment with photosensitivity-enhancing medications or conditions such as porphyria)

Study Design


Intervention

Combination Product:
Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined
The wIRA device applies hyperthermia by heating the treatment area (with maximum surface temperature set to 43° C), aiming to make cancer cells more sensitive to radiation therapy for non-melanoma skin cancer combined with radiotherapy.
Radiation:
Radiotherapy (RT)
Radiotherapy is applied.

Locations

Country Name City State
Switzerland Luzerner Kantonsspital Luzern
Switzerland Kantonsspital Winterthur Winterthur Kanton Zuerich

Sponsors (2)

Lead Sponsor Collaborator
Kantonsspital Winterthur KSW Luzerner Kantonsspital

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Local control The primary outcome is local control, defined as the absence of of recurrence or need for subsequent intervention. Within two years post-treatment initiation.
Secondary Analysis Radiation is applied assessed immediately post-treatment, at six weeks, and three months post-treatment using Common Terminology Criteria for Adverse events (CTCAE 5.0). Immediately (within 24 hours post-treatment), at six weeks post-treatment and at three months post-treatment.
Secondary Late toxicities Monitoring late toxicities, specifically noted at six months, one year, and two years after completion of treatment using Common Terminology Criteria for Adverse events (CTCAE 5.0). at 6months, one year and two years post-treatment
Secondary Quality of life assessment Evaluations are carried out at time of inclusion, immediately post-treatment, at three months, 6months, one year and two years post-treatment utilizing the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Elderly (QLQ-ELD14) questionnaire. at three months, 6months, one year and two years post-treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04552990 - Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma Phase 2
Completed NCT04229277 - Fast Track Diagnosis of Skin Cancer by Advanced Imaging N/A
Completed NCT05608902 - Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
Completed NCT05077033 - Intratumoral phIL12 GET Phase 1
Active, not recruiting NCT04928222 - Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II) Phase 1/Phase 2
Recruiting NCT04929535 - Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment Phase 2
Completed NCT02662244 - Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma N/A
Completed NCT00959647 - A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study Phase 2
Completed NCT00586040 - Photochemical Tissue Bonding Phase 2
Completed NCT00793169 - Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
Completed NCT00473343 - Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma Phase 3
Active, not recruiting NCT06024629 - cOCT Versus LC-OCT for Diagnosing Basal Cell Carcinoma: a Diagnostic Cohort Study
Not yet recruiting NCT05324202 - New Imaging Procedures and Therapeutic Approach in Basal Cell Carcinoma Management N/A
Withdrawn NCT04099446 - A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Completed NCT01208831 - An East Asian Study of LDE225 Phase 1
Completed NCT01260987 - Fractional CO2 Laser Assisted Photodynamic Therapy Phase 2/Phase 3
Completed NCT01201915 - A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma Phase 2
Completed NCT01014819 - A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions N/A
Completed NCT00472043 - PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma Phase 3